+Search query
-Structure paper
| Title | Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2. |
|---|---|
| Journal, issue, pages | J Exp Med, Vol. 222, Issue 12, Year 2025 |
| Publish date | Dec 1, 2025 |
Authors | Siriruk Changrob / Atsuhiro Yasuhara / Suncheol Park / Sandhya Bangaru / Lei Li / Chloe A Troxell / Peter J Halfmann / Steven A Erickson / Nicholas J Catanzaro / Meng Yuan / Panpan Zhou / Min Huang / G Dewey Wilbanks / Joshua J C McGrath / Gagandeep Singh / Sean A Nelson / Yanbin Fu / Nai-Ying Zheng / Sofia M Carayannopoulos / Haley L Dugan / Dustin G Shaw / Christopher T Stamper / Maria Lucia L Madariaga / Florian Krammer / Raiees Andrabi / Dennis R Burton / Andrew B Ward / Ian A Wilson / Yoshihiro Kawaoka / Patrick C Wilson / ![]() |
| PubMed Abstract | The S2 subunit of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is highly conserved across coronavirus strains and therefore is a potential pan-coronavirus vaccine target. ...The S2 subunit of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is highly conserved across coronavirus strains and therefore is a potential pan-coronavirus vaccine target. However, antibodies targeting this region are typically non-neutralizing. We report herein that S2-targeting antibodies from patients who recovered from SARS-CoV-2 infection bound only closely related sarbecovirus subgenus strains and, like most known S2 antibodies, none of these were neutralizing. In contrast, first-exposure, severe acutely infected COVID-19 patients predominantly induced back-boosted antibody-secreting cells imprinted against past common cold coronavirus strain OC43 that were cross-reactive to as many as five subgenera of betacoronavirus strains and gave rise to antibodies that were neutralizing and protective. The antibodies targeted two different sites: one defined by competition with stem helix antibodies, and the second to an underdescribed epitope at the apex of S2. These findings suggest that S2-targeted vaccines could strategically exploit controlled OC43 priming followed by SARS-CoV-2 boosting to enhance the breadth and quality of protective antibody responses. |
External links | J Exp Med / PubMed:41066082 |
| Methods | EM (single particle) |
| Resolution | 3.59 - 5.7 Å |
| Structure data | EMDB-48548, PDB-9mr1: ![]() EMDB-48549: SARS-CoV-2 S2 monomer in complex with NICA01B-1113 Fab EMDB-48550, PDB-9mr2: |
| Chemicals | ![]() ChemComp-NAG: |
| Source |
|
Keywords | VIRUS / SARS-CoV-2 / Spike / S2 / COVID / monoclonal antibody / complex / Viral protein / Viral protein-immune system complex |
Movie
Controller
Structure viewers
About Yorodumi Papers



Authors

External links





homo sapiens (human)
Keywords